Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy

Franck Villain, Jean Marie Parel, Katalin Kiss, Richard K. Parish, François Kühne, Yoshiko Takesue, Patrick Hostyn

Research output: Contribution to journalConference article

1 Citation (Scopus)

Abstract

Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

Original languageEnglish (US)
Pages (from-to)240-244
Number of pages5
JournalProceedings of SPIE - The International Society for Optical Engineering
Volume1877
DOIs
StatePublished - Jun 24 1993
EventOphthalmic Technologies III 1993 - Los Angeles, United States
Duration: Jan 17 1993Jan 22 1993

Fingerprint

glaucoma
Implant
Fluorouracil
Therapy
therapy
Drugs
drugs
Laser surgery
Laser
surgery
Implantation
Lasers
implantation
intraocular pressure
Pharmaceutical Preparations
Surgery
lasers
wound healing
Filtering
Modulation

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Condensed Matter Physics
  • Computer Science Applications
  • Applied Mathematics
  • Electrical and Electronic Engineering

Cite this

Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy. / Villain, Franck; Parel, Jean Marie; Kiss, Katalin; Parish, Richard K.; Kühne, François; Takesue, Yoshiko; Hostyn, Patrick.

In: Proceedings of SPIE - The International Society for Optical Engineering, Vol. 1877, 24.06.1993, p. 240-244.

Research output: Contribution to journalConference article

Villain, Franck ; Parel, Jean Marie ; Kiss, Katalin ; Parish, Richard K. ; Kühne, François ; Takesue, Yoshiko ; Hostyn, Patrick. / Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy. In: Proceedings of SPIE - The International Society for Optical Engineering. 1993 ; Vol. 1877. pp. 240-244.
@article{e7b34e2720bc4839a11a2e4db4a14ad3,
title = "Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy",
abstract = "Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.",
author = "Franck Villain and Parel, {Jean Marie} and Katalin Kiss and Parish, {Richard K.} and Fran{\cc}ois K{\"u}hne and Yoshiko Takesue and Patrick Hostyn",
year = "1993",
month = "6",
day = "24",
doi = "10.1117/12.147533",
language = "English (US)",
volume = "1877",
pages = "240--244",
journal = "Proceedings of SPIE - The International Society for Optical Engineering",
issn = "0277-786X",
publisher = "SPIE",

}

TY - JOUR

T1 - Laser sclerectomy and 5-FU controlled drug release biodegradable implant for glaucoma therapy

AU - Villain, Franck

AU - Parel, Jean Marie

AU - Kiss, Katalin

AU - Parish, Richard K.

AU - Kühne, François

AU - Takesue, Yoshiko

AU - Hostyn, Patrick

PY - 1993/6/24

Y1 - 1993/6/24

N2 - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

AB - Laser sclerectomy, a simple filtering procedure to alleviate high intraocular pressure in glaucoma patients, was thought to offer longer lasting effects than the standard trabeculectomy procedure, thereby improving the patient's outcome. Recent clinical trials have shown that this was not the case and that pharmacologic wound healing modulation is also required with this new procedure. 5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery. However, efficacy depends upon maintaining sustained drug levels, currently achieved by repeated daily injection of the drug for several weeks. To overcome this limitation, we designed a biodegradable implant for the sustained release of 5-FU. After laser sclerectomy, the implant is inserted through the same 1 mm wide conjunctival snip incision then positioned below the open channel. Implantation takes less than a minute. The implant releases the drug over 15 days and totally biodegrades in less than 100 days. The combined laser surgery and implantation procedure shows great potential for the treatment of glaucoma.

UR - http://www.scopus.com/inward/record.url?scp=9044237851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044237851&partnerID=8YFLogxK

U2 - 10.1117/12.147533

DO - 10.1117/12.147533

M3 - Conference article

AN - SCOPUS:9044237851

VL - 1877

SP - 240

EP - 244

JO - Proceedings of SPIE - The International Society for Optical Engineering

JF - Proceedings of SPIE - The International Society for Optical Engineering

SN - 0277-786X

ER -